On the basis of sex: male vs. female rat adenosine A1/A2A receptor affinity

BMC Res Notes. 2023 Aug 10;16(1):165. doi: 10.1186/s13104-023-06346-7.

Abstract

Objective: To ensure reproducibility in biomedical research, the biological variable sex must be reported; yet a reason for using male (instead of female) rodents is seldom given. In our search for novel adenosine receptor ligands, our research group routinely determines a test compound's binding affinities at male Sprague-Dawley rat (r) adenosine A1 and A2A receptors via in vitro radioligand binding studies. This pilot study compared the binding affinities of four adenosine receptor ligands (frequently used as reference standards) at male and female adenosine rA1 and rA2A receptors.

Results: The inhibition constant (Ki) values determined using female rats correspond well to the values obtained using male rats and no markable difference could be observed in affinity and selectivity of reference standards. For example, DPCPX the selective adenosine A1 receptor antagonist: male rA1Ki: 0.5 ± 0.1 nM versus female rA1Ki: 0.5 ± 0.03 nM; male rA2AKi: 149 ± 23 nM versus female rA2AKi: 135 ± 29 nM. From the limited data at hand, we conclude that even when using female rats for in vitro studies without regard for the oestrous cycle, the obtained data did not vary much from their male counterparts.

Keywords: Radioligand binding assays; Rat adenosine A1/A2A receptors; Sex differences.

MeSH terms

  • Adenosine* / pharmacology
  • Animals
  • Female
  • Ligands
  • Male
  • Pilot Projects
  • Purinergic P1 Receptor Antagonists*
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Purinergic P1 / metabolism
  • Reproducibility of Results

Substances

  • Adenosine
  • Ligands
  • Purinergic P1 Receptor Antagonists
  • Receptors, Purinergic P1